VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
VITASPRING BIOMEDICAL CO. LTD.
Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 17, 2026
$0.03+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $6.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.9682 (−96.82%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
VITASPRING BIOMEDICAL CO. LTD. reported revenue of $0 for the twelve months to Jul 31, 2026.
Revenue
$0
TTM Q2 2027
Operating income
-$454.86K
TTM Q2 2027
EPS, diluted
$0.00
TTM Q2 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $6.58M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$455.64K
- EPS, diluted
- $0.00
- Book value per share
- -$0.02
- Diluted shares
- 207M
Ten years at a glance
Fiscal years 2017 to 2026 and trailing twelve months, USD
Revenue
$0
Gross profit
–
Operating income
-$454.86K
Net income
-$455.64K
EPS, diluted
$0.00
Free cash flow
–
Reported periodTrailing twelve months